Inhibikase Therapeutics (IKT) Institutional Ownership $2.64 +0.11 (+4.35%) (As of 11/1/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$713.39KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$431.60K Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024Armistice Capital LLC589,575$713K0.0%N/A8.170% 11/15/2023Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023Barclays PLC11,455$41K0.0%N/A0.214% 8/8/2023Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023Blair William & Co. IL229,000$114K0.0%+27.9%0.817% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% 5/6/2022Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022Redmond Asset Management LLC122,682$182K0.1%N/A0.486% 2/14/2022Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% 11/16/2021Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021Sabby Management LLC421,200$1.18M0.2%N/A4.157% 8/13/2021Altium Capital Management LP109,749$307K0.1%N/A1.083% 8/13/2021Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/21/2021Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/18/2021Millennium Management LLC11,224$67K0.0%N/A0.112% 5/18/2021Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/17/2021HRT Financial LP11,614$69K0.0%N/A0.115% (Data available from 1/1/2016 forward) IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, the following institutional investors and hedge funds held shares of Inhibikase Therapeutics shares: Armistice Capital LLC ($713K), Blair William & Co. IL ($114K), and Hamilton Lane Advisors LLC ($50K), Barclays PLC ($41K).Learn more on IKT's institutional investors. What percentage of Inhibikase Therapeutics stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics stock? The following institutional investors have purchased Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($589.58K), Hamilton Lane Advisors LLC ($82.82K), Blair William & Co. IL ($50K), and Barclays PLC ($11.46K). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 733,847 shares in the last 24 months. This purchase volume represents approximately $1.44M in transactions. Which Inhibikase Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), and Hamilton Lane Advisors LLC ($69.02K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 379,516 shares in the last 24 months. This volume of shares sold represents approximately $1.93M in transactions. Related Companies ELUT Major Shareholders MGX Major Shareholders ZIVO Major Shareholders OMGA Major Shareholders ENTX Major Shareholders CDTX Major Shareholders DTIL Major Shareholders CVM Major Shareholders BLUE Major Shareholders QNCX Major Shareholders This page (NYSE:IKT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
